|Day Low/High||65.30 / 67.42|
|52 Wk Low/High||65.36 / 181.83|
I learned from Jim Cramer long ago to focus on what can go right if you want to ride the momentum of stocks.
Much of the action right now is positioning and tax moves that have little to do with fundamentals or technical conditions.
There is no respite today from the poor price action in individual stocks.
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
Few parts of this biotech space are more frustrating that what I have dubbed 'Tier 3' biotech concerns.
This trading is starting to create some fairly deep pullbacks.
In a red flag for investors, the charts show sellers are getting more aggressive with Sarepta.
Luck is our constant companion in the stock market and we are fools if we ignore that fact.
Can they finally put some points on the board?
Stick to your methodology and don't let worry of underperformance push you to shift your approach.
There are obvious signs that people are trying to put cash to work.
After two chaotic days, Wall Street is trading relatively calmly, creating opportunities for individual names to show life.
This is a battleground stock that has made big moves in both directions on earnings in the past.
The pressure on financials is affecting the entire market.
If you are interested in Square longer term be patient and wait for the drama to end.
The stock still needs to do more work to be convincing.
I'm not yet convinced that this poor action is the start of a major change in market character.
Blue chip name PEP is a good example of the weak action in individual stocks.
It's an interesting story but there are better places for your funds.
This options trade gives the position plenty of time to work.
Traders are likely remembering what Facebook stock did when Mark Zuckerberg testified before Congress.
It is the poster boy for the havoc that internet retailers have wrecked on brick and mortar retailers.
The indices are being jerked around on some news headlines today.
After recent weakness in the biotech sector, here are some names to start watching.